Triplicate groups of Atlantic salmon (Salmo salar L.) were fed four diets containing different oils as the sole lipid source, i.e., capelin oil, oleic acid-enriched sunflower oil, a 1:1 (w/w) mixture of capelin oil and oleic acid-enriched sunflower oil, and palm oil (PO). The beta-oxidation capacity, protein utilization, digestibility of dietary fatty acids and fatty acid composition of lipoproteins, plasma, liver, belly flap, red and white muscle were measured. Further, the lipid class and protein levels in the lipoproteins were analyzed. The different dietary fatty acid compositions did not significantly affect protein utilization or beta-oxidation capacity in red muscle. The levels of total cholesterol, triacylglycerols, and protein in very low density lipoprotein (VLDL), low density lipoprotein (LDL), high density lipoprotein (HDL), and plasma were not significantly affected by the dietary fatty acids. VLDL, LDL, and HDL fatty acid compositions were decreasingly affected by dietary fatty acid composition. Dietary fatty acid composition significantly affected both the relative fatty acid composition and the amount of fatty acids (mg fatty acid per g tissue, wet weight) in belly flap, liver, red and white muscle. Apparent digestibility of the fatty acids, measured by adding yttrium oxide as inert marker, was significantly lower in fish fed the PO diet compared to the other three diets.

No abstract

No abstract

Atlantic salmon (Salmo salar L.) juveniles were fed either 100% fish oil (FO), 75% vegetable oil (VO), or 100% VO throughout their life cycle to harvest weight followed by a finishing diet period when all groups were fed 100% FO. The two experimental VO diets were tested at two different locations (Scotland and Norway) against the same control diet (100% FO). The VO blend was composed of rapeseed oil, palm oil, and linseed oil using capelin oil as a control for fatty acid class compositions. Flesh fatty acid profiles were measured regularly throughout the experiment, with the times of sampling determined by changes in pellet size/lipid content and fish life stage. Growth and mortality rates were not significantly affected by dietary fatty acid compositions throughout the life cycle, except during the seawater winter period in Norway when both growth and protein utilization were increased in salmon fed 100% VO compared to 100% FO. Flesh fatty acid composition was highly influenced by that of the diet, and after the finishing diet period the weekly intake recommendations of very long chain n-3 polyunsaturated fatty acid (VLCn-3 PUFA) for human health were 80 and 56% satisfied by a 200 g meal of 75% VO and 100% VO flesh, respectively. No effect on flesh astaxanthin levels was observed in relation to changing dietary oil sources. Sensory evaluation showed only minor differences between salmon flesh from the dietary groups, although prior to the finishing diet period, flesh from 100% VO had less rancid and marine characteristics and was preferred over flesh from the other dietary groups by a trained taste panel. After the finishing diet period, the levels of typical vegetable oil fatty acids in flesh were reduced, whereas those of VLCn-3 PUFA increased to levels comparable with a 100% FO fed salmon. No differences in any of the sensory characteristics were observed between dietary groups. By blending VOs to provide balanced levels of dietary fatty acids, up to 100% of the fish oil can be replaced by the VO blend without compromising growth or flesh quality. At the same time, 75% of the dietary fish oil can be replaced without compromising flesh VLCn-3 PUFA content, thereby providing a beneficial nutritional profile for human consumption.

Blood samples from healthy adult Atlantic salmon fed an optimal diet in net sea pens were collected at intervals from October to May. Haematological determinations and biochemical serum analyses were carried out on 20 fish in each of seven samples. The ranges of haematological values for sample means were: haematocrit 4449%, haemoglobin 8.9-10-4 g 100 ml-', red blood cell count 0.85-1.10 x lo'* I-', MCV 44-553 x 10-151, MCH 94-106 x g, MCHC 19.4-21.7g IOOml-' and leucocrit 0.43-0.96%. The ranges of enzyme activities in serum, for sample means, were: alkaline phosphatase 647-988 U 1-', aspartate aminotransferase 202-351 U I -' and alanine aminotransferase 4-8 U I -I . The ranges of the other parameters analyzed in serum were: total protein 41,656.6g I-', albumin 18.3-24.3 g I-', albumin/total protein ratio 39.34.0%, creatinine 26-46 pmol, triglycerides 2334.98 mmol and cholesterol 9.3-12-8 mmol. These values are considered to be the normal ranges in healthy fish. Variations due to seasonal changes, and the clinical significance of the selected parameters, are discussed. Data showing the reproducibility of the biochemical analyses in serum are presented.

Six groups of Atlantic salmon, initial weight 142 ± 1 g, were fed increasing dietary inclusion of rapeseed oil (RO) in a regression design and one group was fed a 50% olive oil/ 50% capelin oil diet. Fatty acid composition was measured in red and white muscle, liver, and fatty acid and lipid class composition was measured in plasma and in the lipoproteins; very low density lipoprotein, low density lipoprotein, high density lipoprotein and nonlipoprotein fraction after 22 and 42 weeks of feeding. Further, the activities of liver NADH-isocitrate dehydrogenase (ICDH), malic enzyme, glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase were measured at each sampling point. After 42 weeks of feeding the experimental diets, the tissue and lipoprotein fatty acid composition was highly affected by dietary fatty acid composition. Regressions showed that 22:1n ) 11, 18:1n ) 9, 18:3n ) 3 and 18:2n ) 6 are readily metabolized in all tissues analysed. Further, 20:5n ) 3 seems to be metabolized in muscle and retained in liver. 22:6n ) 3 was selectively retained in all the analysed tissues, and with higher retention in liver and plasma with higher polar lipid/neutral lipid ratio compared to white and red muscle. Liver from salmon fed 100% RO showed decreased G6PDH and increased ICDH activities compared to the other dietary groups; however, no linear relationship related to increased RO inclusion was detected. The amount of plasma lipoproteins, liver monoene fatty acid level and lipogenic enzyme activity decreased from the autumn to the winter sampling with concomitant decrease in temperature. KEY WORDSKEY WORDS: capelin oil, fatty acid retention, fatty acids, glucose-6-phosphate dehydrogenase, high density lipoprotein, isocitrate dehydrogenase, lipid class composition, lipogenic enzymes, low density lipoprotein, malic enzyme, olive oil, 6-phosphogluconate dehydrogenase, rapeseed oil, very low density lipoprotein

No abstract

Aims Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/SCD in ARVC patients. Methods and results Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline, aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interquartile range 2.44–9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight potential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accurately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence interval (CI) 0.73–0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92–0.95)]. By decision curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algorithm with a 20.6% reduction of ICD placements with the same proportion of protected patients ( P < 0.001). Conclusion Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs ( www.arvcrisk.com ).